Antidiarrheal rule
This article was originally published in The Tan Sheet
Executive Summary
Relief of travelers' diarrhea is included as an indication for bismuth subsalicylate products in the final monograph for OTC antidiarrheal drug products, effective June 11, FDA reports in the May 12 Federal Register. The condition is described as "a subset of diarrhea occurring in travelers that is most commonly caused by an infectious agent." The approval responds to requests made in response to the 1986 TFM on antidiarrheals (1"The Tan Sheet" April 21, 2003, p. 4). Web materials for Procter & Gamble's Pepto-Bismol already provide information on the condition...
You may also be interested in...
Bismuth Subsalicylate “Relieves Travelers’ Diarrhea” Claim Proposed by FDA
Relief of travelers' diarrhea would be included as an indication for bismuth subsalicylate products in the OTC antidiarrheal drug final monograph under a proposed rule published in the 1April 17 Federal Register
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.